Plain-English translation of NCT05628922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests whether personalizing cancer treatment based on your individual response helps patients with locally advanced nasopharyngeal cancer live longer and stay cancer-free. All patients start with chemotherapy (a combination called GP), and then doctors measure a specific virus in your blood and scan your neck to see how well the cancer is responding. Depending on your response, you may receive different follow-up treatments—some patients get standard radiation with chemotherapy, while others receive additional immunotherapy medication called before radiation.
Nasopharyngeal cancer is often linked to a virus called Epstein-Barr virus, which can be detected in the blood. This trial is designed to find out whether measuring how quickly this virus disappears after initial treatment can help doctors decide who needs more aggressive treatment and who can do well with standard care.
You likely qualify if…
You likely don't qualify if…
You will receive an initial cycle of chemotherapy, followed by blood tests and neck imaging to measure your cancer's response. Based on how well your cancer responds, you will be placed into one of three groups: fast responders proceed directly to radiation with chemotherapy; intermediate responders are randomly assigned to either receive additional immunotherapy medication or standard chemotherapy before radiation; and slow responders receive a different chemotherapy regimen combined with immunotherapy medication before radiation. The study lasts about 2 years, with regular clinic visits, blood work, and imaging scans to monitor your progress and side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China